Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer.

IF 2.4 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Journal of Bone and Mineral Metabolism Pub Date : 2024-11-01 Epub Date: 2024-09-30 DOI:10.1007/s00774-024-01552-0
Han-Sang Baek, Kabsoo Shin, Jinyoung Kim, Chaiho Jeong, Jeongmin Lee, Yejee Lim, Ki-Hyun Baek, Jeonghoon Ha
{"title":"Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer.","authors":"Han-Sang Baek, Kabsoo Shin, Jinyoung Kim, Chaiho Jeong, Jeongmin Lee, Yejee Lim, Ki-Hyun Baek, Jeonghoon Ha","doi":"10.1007/s00774-024-01552-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chemotherapy-induced bone loss (CTIBL) is common among breast cancer patients, requiring comprehensive assessment and intervention. Zoledronic acid, a strong inhibitor of bone resorption, is effective in CTIBL management, though information on dosing and intervals, particularly the efficacy of the 5 mg annual dose for osteoporosis in breast cancer patients, is limited.</p><p><strong>Materials and methods: </strong>In this 12-month prospective observational study, 85 breast cancer patients were divided into three groups: 17 received no treatment, 17 received tamoxifen, and 51 received anastrozole or letrozole (AI). Post-surgery, patients were administered a single 5 mg dose of zoledronic acid and monitored over 12 months for changes in bone mineral density (BMD), fracture rates, and biochemical markers.</p><p><strong>Results: </strong>Initially, the AI group was the oldest, averaging 59.1 ± 8.7 years. At baseline, no significant differences in variables, except age, were observed. After 12 months, BMD increased in all groups following a single zoledronic acid dose, with the smallest increase in the AI group at the lumbar spine: no treatment (2.4% ± 6.1%), tamoxifen (2.6% ± 3.4%), AI (0.6% ± 14.5%) (p = 0.778). CTx and P1NP levels were consistently suppressed up to 12 months post-treatment, with smaller reductions in the AI group. There were no significant differences in fracture or bone metastasis rates among groups.</p><p><strong>Conclusion: </strong>A single infusion of 5 mg zoledronic acid was effective in increasing bone density in breast cancer patients. However, AI-treated patients showed less improvement in vertebral bone mineral density and biochemical markers. Further long-term studies with larger cohorts are needed.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"720-727"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00774-024-01552-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chemotherapy-induced bone loss (CTIBL) is common among breast cancer patients, requiring comprehensive assessment and intervention. Zoledronic acid, a strong inhibitor of bone resorption, is effective in CTIBL management, though information on dosing and intervals, particularly the efficacy of the 5 mg annual dose for osteoporosis in breast cancer patients, is limited.

Materials and methods: In this 12-month prospective observational study, 85 breast cancer patients were divided into three groups: 17 received no treatment, 17 received tamoxifen, and 51 received anastrozole or letrozole (AI). Post-surgery, patients were administered a single 5 mg dose of zoledronic acid and monitored over 12 months for changes in bone mineral density (BMD), fracture rates, and biochemical markers.

Results: Initially, the AI group was the oldest, averaging 59.1 ± 8.7 years. At baseline, no significant differences in variables, except age, were observed. After 12 months, BMD increased in all groups following a single zoledronic acid dose, with the smallest increase in the AI group at the lumbar spine: no treatment (2.4% ± 6.1%), tamoxifen (2.6% ± 3.4%), AI (0.6% ± 14.5%) (p = 0.778). CTx and P1NP levels were consistently suppressed up to 12 months post-treatment, with smaller reductions in the AI group. There were no significant differences in fracture or bone metastasis rates among groups.

Conclusion: A single infusion of 5 mg zoledronic acid was effective in increasing bone density in breast cancer patients. However, AI-treated patients showed less improvement in vertebral bone mineral density and biochemical markers. Further long-term studies with larger cohorts are needed.

单次输注 5 毫克唑来膦酸预防绝经后乳腺癌妇女骨质流失和骨折的疗效。
简介化疗引起的骨质流失(CTIBL)在乳腺癌患者中很常见,需要进行全面评估和干预。唑来膦酸是一种强效的骨吸收抑制剂,可有效控制 CTIBL,但有关剂量和间隔的信息有限,尤其是每年 5 毫克的剂量对乳腺癌患者骨质疏松症的疗效:在这项为期 12 个月的前瞻性观察研究中,85 名乳腺癌患者被分为三组:17 人未接受治疗,17 人接受他莫昔芬治疗,51 人接受阿那曲唑或来曲唑(AI)治疗。手术后,患者接受单次5毫克剂量的唑来膦酸治疗,并在12个月内监测骨矿物质密度(BMD)、骨折率和生化指标的变化:最初,人工智能组年龄最大,平均为 59.1 ± 8.7 岁。除年龄外,基线变量无明显差异。12 个月后,在服用单剂量唑来膦酸后,所有组的 BMD 均有所增加,其中人工授精组腰椎的 BMD 增幅最小:无治疗组(2.4% ± 6.1%)、他莫昔芬组(2.6% ± 3.4%)、人工授精组(0.6% ± 14.5%)(P = 0.778)。CTx 和 P1NP 水平在治疗后 12 个月内持续下降,AI 组下降幅度较小。各组间骨折或骨转移发生率无明显差异:结论:单次输注 5 毫克唑来膦酸可有效增加乳腺癌患者的骨密度。结论:单次输注 5 毫克唑来膦酸可有效增加乳腺癌患者的骨密度,但 AI 治疗患者的脊椎骨矿物质密度和生化指标改善较少。还需要进行更大规模的长期研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Bone and Mineral Metabolism
Journal of Bone and Mineral Metabolism 医学-内分泌学与代谢
CiteScore
6.30
自引率
3.00%
发文量
89
审稿时长
6-12 weeks
期刊介绍: The Journal of Bone and Mineral Metabolism (JBMM) provides an international forum for researchers and clinicians to present and discuss topics relevant to bone, teeth, and mineral metabolism, as well as joint and musculoskeletal disorders. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. Acceptance is based on the originality, significance, and validity of the material presented. The journal is aimed at researchers and clinicians dedicated to improvements in research, development, and patient-care in the fields of bone and mineral metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信